Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

New therapeutic options in uveitis

S Lightman1

  • 1Department of Clinical Ophthalmology, Moorfields Eye Hospital, London, UK. s.lightman@ucl.ac.uk

Eye (London, England)
|January 1, 1997
PubMed
Summary

Systemic medications for sight-threatening posterior uveitis can cause severe side effects. Future treatments may involve sustained intraocular drug delivery to improve eye drug levels without systemic administration.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Feasibility of salivary cortisol collection in patients and companions attending dementia diagnostic meetings in memory clinics.

BMC research notes·2021
Same author

Growth hormone secretion, fatigue and quality of life after childhood traumatic brain injury.

European journal of endocrinology·2019
Same author

Pegylated interferon-α-2b reduces corticosteroid requirement in patients with Behçet's disease with upregulation of circulating regulatory T cells and reduction of Th17.

Annals of the rheumatic diseases·2014
Same author

Visual prognosis in Behçet's disease.

Ocular immunology and inflammation·2012
Same author

Systemic steroid prophylaxis for cataract surgery in patients with posterior uveitis.

Ocular immunology and inflammation·2012
Same author

Primary trabeculectomy with 5-fluorouracil for glaucoma secondary to uveitis.

Ocular immunology and inflammation·2012

Area of Science:

  • Ophthalmology
  • Immunology

Background:

  • Sight-threatening posterior uveitis often requires systemic medication for disease control.
  • Current systemic treatments offer short-term visual improvement but carry risks of severe side effects.
  • Cyclosporine is a second-line option but not universally effective or tolerated.

Purpose of the Study:

  • To review emerging therapeutic approaches for managing posterior uveitis.
  • To explore the potential of novel treatments for improved patient outcomes.
  • To assess strategies that minimize systemic drug exposure and side effects.

Main Methods:

  • Literature review of current and investigational therapies for posterior uveitis.
  • Analysis of systemic and local treatment modalities.
  • Examination of drug delivery systems focusing on intraocular administration.

Main Results:

  • Existing systemic drugs have limitations in efficacy and tolerability.
  • Severe systemic side effects are a significant concern with current treatments.
  • Sustained intraocular drug delivery shows promise for localized treatment.

Conclusions:

  • There is a need for safer and more effective treatments for posterior uveitis.
  • Sustained intraocular drug delivery represents a promising strategy to achieve therapeutic drug levels within the eye.
  • This approach could potentially avoid the systemic side effects associated with current medications.

Related Experiment Videos